Product Code: RP-ID-10293953 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10293953
Market Overview:
Biosimilars Market, By Product Type (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Application (Oncology, Blood Disorders, Infectious Diseases, Autoimmune Diseases, Other Diseases) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025
REPORT HIGHLIGHT
The “Global Biosimilars Market- – Industry Analysis, Share, Trend, Market Size and Forecast” was estimated to be around US$ 50.0 billion in 2016 and is anticipated to grow with 55.0% of growth rate during the future period. This report segments the global Biosimilars Market by product type, application and geography. Biosimilars are the biologics pharmaceutical drugs which are similar to the reference biologic products. These drugs are an interchangeable biological product that contains synthetically developed protein molecules. When the patent of branded drug is expired, pharmaceutical companies are planning to develop off-patent biologics i.e. biosimilars that offer similar biological activity. The biosimilars market offers many growth opportunities and driving factors as compared to the restraining factors. It is stated by various research scientists that development of biosimilars will drastically reduce the price of pharmaceutical drugs.
In terms of product types, the market for recombinant glycosylated proteins continue to dominate during the forecast period, while the market for recombinant non-glycosylated proteins biosimilars will see a huge potential during the forecast period. On other side, oncology was the largest application segment in 2016, and expected to be the fastest growing application segment in the forecast period. The rise in the aging population, increasing cancer patients, and rise of hospital acquired infection patients globally are factors responsible for the growth of this application segment. The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment.
The report aims at estimating the market size and future growth potential of market across different segments, such as product types, application and regions. The years considered for the study are:
Historical Year – 2014 & 2015
Base Year – 2015
Estimated Year – 2016
Projected Year – 2025
Companies reported in this report are: Amgen, Inc, AstraZeneca, Pfizer, Inc., BIOCON Limited, Novartis AG, STADA, Teva Pharmaceuticals Inc. and Others. For company profiles in the report, 2014 has been considered. Where information is unavailable for the base year, the prior year has been considered.
TARGET AUDIENCE
Hospitals
Manufacturers
Traders, Distributors, And Suppliers of Biosimilars
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The research report categorizes the Biosimilars Market in each of the following submarkets to forecast the revenues and analyze the trends:
GLOBAL BIOSIMILARS MARKET, BY PRODUCT TYPES
Recombinant Glycosylated Proteins
Recombinant Non-Glycosylated Proteins
Recombinant Peptides
GLOBAL BIOSIMILARS MARKET, BY APPLICATION
Oncology
Blood Disorders
Infectious Diseases
Autoimmune Diseases
Others
GLOBAL BIOSIMILARS MARKET, BY REGION
North America
Europe
Asia Pacific
Rest of the World
GLOBAL BIOSIMILARS MARKET, GEOGRAPHIC ANALYSIS
Further Breakdown of The North America Biosimilars Market
U.S.
Canada
Further Breakdown of The Europe Biosimilars Market
Germany
France
Rest of Europe
Further Breakdown of The APAC Biosimilars Market
India
China
Rest of APAC
Further Breakdown of The Rest of the World Biosimilars Market
Middle East and Africa
Latin America
Related Reports
Proof of Quality & Reliability
